Revenue Comparison
Chart: Revenue Comparison. Values in USD billions. In Q2 2026: Eli Lilly 22.974, Viking Therapeutics 0.
Eli Lilly vs Viking Therapeutics Net Worth and Market Cap
Eli Lilly (LLY) and Viking Therapeutics (VKTX) are peers in GLP-1. Eli Lilly reported revenue of $23.0B as of Q2 2026, compared with $0 for Viking Therapeutics. Eli Lilly leads on revenue.
Key differences
- Eli Lilly's KPIs on Sterling include Cardiometabolic Manufacturing Capex Announcements by Site (Cumulative) and Foundayo Quarterly Revenue.
- Viking Therapeutics's KPIs on Sterling include Cash + Short-Term Investments (Quarterly) and Viking Oral VK2735 Phase 3 Timing.
Latest Quarter Comparison
Table: Latest Quarter Comparison. 15 rows across Metric, Eli Lilly, Viking Therapeutics.| Metric | Eli Lilly | Viking Therapeutics |
|---|---|---|
| Market Cap | - | - |
| Revenue | $22.97B | $0 |
| Cost of Revenue | $3.27B | $0 |
| Gross Profit | $19.71B | $0 |
| Operating Income | $12.46B | $-164.00M |
| Net Income | $7.09B | $-158.00M |
| R&D Expense | $3.82B | $150.00M |
| Earnings Per Share | $7.94 | -$1.37 |
| Gross Margin | 85.8% | - |
| Operating Margin | 54.2% | - |
| Net Profit Margin | 30.9% | - |
| Free Cash Flow | $7.76B | $-114.00M |
| Cumulative Free Cash Flow | $109.66B | $-747.00M |
| Operating Cash Flow | $10.69B | $-114.00M |
| Cash & Equivalents | $8.89B | $118.00M |